Drug Database
Back to search

Poland· PL-100505733

Adzynma

A apadamtase alfa und cinaxadamtase alfa product containing radamts13, registered in Poland by Takeda Manufacturing Austria AG. The same ATC class is registered in 10 of our 19 countries.

ATC B01AD13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAdzynmaATCB01AD13REGISTER NO.PL-100505733PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about radamts13Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Apadamtase alfa und cinaxadamtase alfa is registered in 10 of 19 countries.

Countries holding a registration under ATC B01AD13 (apadamtase alfa und cinaxadamtase alfa), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search apadamtase alfa und cinaxadamtase alfa products by name

Apadamtase alfa und cinaxadamtase alfa · ATC B01AD13

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
rADAMTS13
Manufacturer
Takeda Manufacturing Austria AG
Country
Poland (PL)
ATC code
B01AD13
ATC class
Apadamtase alfa und Cinaxadamtase alfa
Defined daily dose
200 E, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    07038319165922
  • gtin
    04150193723135

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under B01AD13

Apadamtase alfa und cinaxadamtase alfa, as other registers publish it.

All apadamtase alfa und cinaxadamtase alfa products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a95bb9cd-6fb7-4259-aa02-5a315449ed6b
GET /v1/drugs/a95bb9cd-6fb7-4259-aa02-5a315449ed6b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "500 IU",
  "packaging": "07038319165922 ¦ Rpz ¦ EU/1/24/1837/001 ¦ 158181\n1 strzyk. 10 ml + jedno urządzenie do rekonstytucji (BAXJECT II Hi-Flow) + jeden zestaw infuzyjny z igłą 25G + 2 waciki nasączone alkoholem ¦ 1 fiol.  proszku ¦ 1 fiol. 5 ml rozpuszczalnika\n¦ UR/Z/4b/041/25 - 04150193723135",
  "substance": "rADAMTS13 100 IU/ml",
  "common_name": "rADAMTS13",
  "pl_product_id": "100505733",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about apadamtase alfa und cinaxadamtase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console